CRC tissues; adjacent normal tissues; serum; serum exosomes; tumor tissues; tissue microarray
HCT116; Colo320; 293T
cell line-derived xenograft; patient-derived xenograft
proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); apoptosis (inhibits); EMT (promotes); ceRNA regulation (promotes); ubiquitination (inhibits); other pathway/process (promotes)
Microarray; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; FISH / smFISH; Clinical Sample Validation; Cohort Study; Survival Analysis; ROC Analysis; Bioinformatics Analysis; RNA Pull-Down; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; RNA-seq; Transfection; CCK8; EdU Staining; Colony Formation Assay; Annexin V/PI Flow Cytometry; Transwell Assay; Wound Healing Assay; Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model; H&E Staining; Digital PCR
CircZFR is a promising biomarker for CRC diagnosis and prognosis; high circZFR levels are associated with advanced stage, lymph node and distant metastases, and shorter overall survival; serum circZFR may serve as a liquid biopsy marker.
CircZFR is an up-regulated oncogenic circRNA in colorectal cancer tissues and serum exosomes, associated with advanced stage, metastasis, diagnostic value, and poor overall survival. Functionally, it promotes CRC proliferation, migration, invasion, tumor growth and metastasis while inhibiting apoptosis. Mechanistically, ESRP1 enhances circZFR biogenesis, circZFR stabilizes BCLAF1 by preventing ubiquitin-proteasome degradation, and circZFR acts as a sponge for miR-3127-5p to increase RTKN2 expression.
0.9007
CircZFR promotes colorectal cancer progression via stabilizing BCLAF1 and regulating the miR-3127-5p/RTKN2 axis.
combined biological and clinical study